Sign In
Buy NXL
$0.533
-0.0175 (-3.18%)
At Close: Jun 03, 2026
HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)
Nexalin Technology (NASDAQ:NXL) Shares Down 10.9% – Time to Sell?
04:03am, Tuesday, 16'th Dec 2025
Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report)'s share price fell 10.9% on Monday. The stock traded as low as $0.8101 and last traded at $0.82. 375,300 shares changed hands during trading, a
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program
08:00am, Wednesday, 03'rd Dec 2025
HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4
08:00am, Tuesday, 02'nd Dec 2025
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m.
HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
09:15am, Thursday, 13'th Nov 2025
Appointment Follows Israeli Ministry of Health Approval for Nexalin's Gen-2 SYNC Device Appointment Follows Israeli Ministry of Health Approval for Nexalin's Gen-2 SYNC Device
Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia
08:30am, Wednesday, 05'th Nov 2025
HOUSTON, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain
MNTN (NYSE:MNTN) and Nexalin Technology (NASDAQ:NXL) Critical Analysis
01:48am, Sunday, 02'nd Nov 2025
MNTN (NYSE: MNTN - Get Free Report) and Nexalin Technology (NASDAQ: NXL - Get Free Report) are both small-cap business services companies, but which is the better stock? We will compare the two busine
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
08:30am, Thursday, 30'th Oct 2025
HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain
HOUSTON, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of th
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
08:00am, Friday, 10'th Oct 2025
HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of th
Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?
02:45pm, Wednesday, 08'th Oct 2025
Nexalin Technology Inc. (NASDAQ:NXL) stock spiked on Wednesday, with a massive session volume of 167.9 million compared to the average volume of 972.2 thousand, as per data from Benzinga Pro.
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device
08:30am, Wednesday, 08'th Oct 2025
40-Hz DIFS™ significantly improves cognitive performance and brain connectivity in peer-reviewed clinical trial Results published in Radiology, the flagship journal of the Radiological Society of No
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
08:30am, Thursday, 25'th Sep 2025
HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of t
